The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Community Fast Track, 2003The regulation of synaptic dopamine by striatal nicotinic receptors
A new category of drugs that offer a promising therapy for Parkinson's disease are drugs that act at a key subtype of brain receptors for the neurotransmitter acetylcholine, the nicotine-sensitive...
-
Community Fast Track, 2003Intracellular Trafficking Dysfunction Caused by Alpha-synuclein Aggregation
A growing body of evidence suggests that aggregation of a neuronal protein named a-synuclein might be the fundamental cause of many neurodegenerative diseases, such as Parkinson's disease (PD)...
-
Community Fast Track, 2003Analysis of genetic factors influencing alpha-synuclein toxicity
Parkinson's disease is a devastating disease that robs its victims of the ability to direct and control normal movement. These symptoms result from the death of a particular class of nerve cell in the...
-
Community Fast Track, 2003Adenosine A2A Receptors in a Pre-clinical Model of PD Dyskinesias
Gradual slowing of movement in Parkinson's disease (PD) is due to the steady decline in brain levels of dopamine, a chemical signal that facilitates normal movement. Our most effective medications for...
-
Community Fast Track, 2003Morphology Specific Antibodies as Potential Therapeutics
Parkinson's Disease has been correlated with the over expression and misfolding of the protein a-synuclein. This protein is abundantly produced in nerve cells in the brain and is the major component...
-
Community Fast Track, 2003Anti-inflammatory Effects of Nicotine in Parkinson’s Disease
Parkinson's disease (PD) is a progressive, debilitating movement disorder resulting from the death of the dopamine-synthesizing neurons and, consequently, dopamine deficiency in the basal ganglia, i.e...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.